Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie director Jennifer L. Davis to resign from board effective November 2, 2026

Neutral Impact 2 of 5 leadership

AbbVie disclosed that Class II director Jennifer L. Davis intends to resign from its Board of Directors, effective November 2, 2026, after her recent appointment as Chief Executive Officer at Align Technology, Inc. The filing states her resignation is not the result of any disagreement with AbbVie on its operations, policies or practices. The change is a board composition update with no financial figures attached.

Key points

  • Jennifer L. Davis, a Class II director, notified the Board on October 28, 2026 of her intent to resign.
  • Resignation is effective November 2, 2026.
  • Reason given: her recent appointment as Chief Executive Officer at Align Technology, Inc.
  • The filing states there was no dispute or disagreement with AbbVie on its operations, policies or practices.

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:05 PM ET
Accession number0001104659-26-121322

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.